apitegromab tirzepatide for lean mass preservation during tirzepatide-induced weight loss: a randomized, double-blind, placebo-controlled phase 2 trial Drug apitegromab may stop muscle

A 2024 survey by the Research Society for the Study of Diabetes in India found that less than a third of general practitioners in non-metro cities felt confident initiating GLP-1 therapies

But there are some reports that hint at how the drug may affect mental health in general

Initially developed for diabetes management and then repurposed for obesity treatment, these versatile compounds are now capturing attention for their potential cognitive benefits, further expanding their already impressive repertoire of clinical applications

And Medicare now has a specific pathway for Zepbound coverage when prescribed for obstructive sleep apnea (OSA), with a government agreement expected to cap the copay cost at roughly $50/month starting in 2026

Government programs like Medicare and Medicaid also vary in their coverage, depending on individual circumstances and approved uses